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Abstract
Background: MicroRNAs (miRNAs) represent a class of small non-coding RNAs that control gene expression by targeting
mRNAs and triggering either translation repression or RNA degradation. Emerging evidence suggests the potential
involvement of altered regulation of miRNA in the pathogenesis of cancers, and these genes are thought to function as
both tumor suppressors and oncogenes.
Methodology/Principal Findings: Using microRNA microarrays, we identify several miRNAs aberrantly expressed in human
ovarian cancer tissues and cell lines. miR-221 stands out as a highly elevated miRNA in ovarian cancer, while miR-21 and
several members of the let-7 family are found downregulated. Public databases were used to reveal potential targets for the
highly differentially expressed miRNAs. In order to experimentally identify transcripts whose stability may be affected by the
differentially expressed miRNAs, we transfected precursor miRNAs into human cancer cell lines and used oligonucleotide
microarrays to examine changes in the mRNA levels. Interestingly, there was little overlap between the predicted and the
experimental targets or pathways, or between experimental targets/pathways obtained using different cell lines,
highlighting the complexity of miRNA target selection.
Conclusion/Significance: Our results identify several differentially expressed miRNAs in ovarian cancer and identify
potential target transcripts that may be regulated by these miRNAs. These miRNAs and their targets may have important
roles in the initiation and development of ovarian cancer.
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Introduction
MicroRNAs (miRNAs) are 21–23 nucleotide regulatory RNAs
processed from 70–100 nucleotide hairpin pre-miRNAs [1,2]. The
miRNA are incorporated into a ribonucleoprotein complex called
RNA-induced silencing complex (RISC) and guide the RISC to
the target mRNA [3]. Binding of the miRNA to the target mRNA
5’UTR can downregulate gene expression through inhibition of
translation or increased RNA degradation. In addition, recent
evidence suggests that miRNA may also upregulate translation
under certain circumstances [4]. Hundreds of miRNAs have been
identified in various species, including C. elegans, humans, and the
plant Arabidopsis thaliana. It is believed that mammalian miRNAs
have the potential to regulate at least 20–30% of all human genes
[5]. Each miRNA can target up to 200 transcripts directly or
indirectly, and multiple miRNAs can target a given gene [6].
Therefore the potential regulatory circuitry afforded by miRNA is
extremely complex. The expression of several miRNAs has been
shown to be developmentally regulated and several studies have
demonstrated that miRNA are responsible for determining cell
fate. These results indicate that miRNAs play a major role in
fundamental cellular processes, including the timing of cellular
development, hematopoiesis, fat metabolism, organogenesis,
apoptosis, cell proliferation, and differentiation. There is also
strong evidence that miRNAs are implicated in the onset and
progression of many diseases, including cancer [3].
Comparison between human cancers and their normal
counterparts have revealed distinct miRNA expression profiles.
Indeed, a number of studies have reported differentially regulated
miRNAs in diverse cancer types such as breast cancer [7], lung
cancer [8], chronic lymphocytic leukemia [9], colon cancer [10],
thyroid carcinomas [11], pancreatic cancer [12], head and neck
cancer [5], prostate cancer [13], pituitary adenomas [14], and
ovarian cancer [15–18]. Collectively, these studies demonstrate
that some human miRNAs are consistently deregulated in human
cancer, suggesting a role for these genes in tumorigenesis. Specific
over-expression or under expression of certain miRNAs has been
shown to correlate with particular tumor types [19]. Overex-
pressed miRNAs could potentially target tumor suppressor genes,
while downregulated miRNAs would theoretically regulate
oncogenes. For example, the let-7 miRNAs, which are down
regulated in lung cancer, can negatively regulate the oncogenes
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of these oncogenes [8,20,21]. Thus, members of the let-7 family
function biologically as tumor suppressors and their loss is
predicted to promote transformation and tumor progression.
Conversely, the human miRNA cluster miR-17-92 acts as an
oncogene in B-cell lymphoma [22] and lung cancer [23], and can
collaborate with myc [22].
Unique miRNA expression signatures have been found to be
associated with bio-molecular and prognostic characteristics of
human lung cancer and chronic lymphocytic leukemia [8,24],
indicating that miRNA signatures could be used to define
biological or clinical features of human cancers. The development
of new miRNA markers in the near future will represent one of the
main goals in molecular medicine as miRNA expression profiles
might better classify poorly differentiated tumors as compared with
the transcript-based classifiers [19].
There is a limited number of studies in the literature on the roles
of miRNAs in ovarian cancer. Zhang et al. reported high
frequency genomic alterations involving miRNA genes in 227
human ovarian cancer, breast cancer and melanoma specimens
[15]. In another study, 84 tissues (15 normal and 69 malignant)
and 5 cell lines were analyzed for alteration in miRNA profile
[16]. Finally a study analyzing 10 ovarian tumors and 10 different
normal controls was recently reported [17]. In this report, we
describe a series of experiments to elucidate the changes in
miRNA expression in ovarian cancer and to identify possible
targets of relevant candidate miRNAs.
Results
miRNA Expression patterns in ovarian tissues
MiRNA expression profiles were determined for 34 ovarian
cancer tissues (Table 1) as well as 10 ovarian cancer cell lines. An
immortalized human ovarian surface epithelium cell line was used
as non-transformed control. The expression profiles were
determined using miRCURY
TM LNA miRNA Arrays. LNAs
are a class of conformationally restricted nucleotide analogs that
increase affinity of an oligonucleotide for its complementary RNA
or DNA target. The Exiqon miRNA array is currently the most
comprehensive probe set available on an array platform and
allows for an in depth analysis of miRNA expression. Following
RNA hybridization and array analysis, samples were clustered
according to their miRNA profile using the hierarchical clustering
algorithm of the JMP 6.0.0 software. Figure 1A shows hierarchical
clustering analysis of tumor tissues and cell lines based on overall
miRNA expression. The profiles shown are relative to ovarian
surface epithelial cells (HOSE-B cells). The samples are separated
into three main clusters. The middle cluster is comprised entirely
of tumors (17 samples), while the left cluster contains 2 cell lines
and 7 primary tumors. The right cluster is enriched in cell lines
and contains 8 cell lines out of 18 members in the cluster. The
hierarchical clustering was then repeated based on a much smaller
number of genes and included only 70 highly differentially
expressed miRNA in ovarian cancer tissues and cell lines. This
clustering analysis gave rise to multiple clusters, but again, the cell
lines clustered together in 2 different clusters while the primary
tissues were grouped together (Figure 1B), suggesting specific
differences in miRNA expression between ovarian cancer tissues
and cell lines.
Using principal component analysis (PCA) we found that global
miRNA expression could distinguish ovarian cancer tumors from
ovarian cancer cell lines (Figure 2). The non-tumorigenic control
HOSE-B also exhibited a unique expression pattern, distinguish-
able from both cell lines and tissues.
Differentially expressed miRNAs
We then identified miRNAs that were differentially expressed
between non-neoplastic and neoplastic samples (Figure 3A,
Table 2). Only miRNAs that were altered at least 2-fold in at
least 60% of the samples were considered significant candidates.
Using these strict criteria, we identified 25 upregulated and 31
downregulated miRNAs between control and cancer tissues.
Similarly, we identified 5 upregulated and 23 downregulated
miRNAs in ovarian cancer cell lines compared with non-
neoplastic HOSE-B cells. 14 miRNAs were deregulated in both
tissues and cell lines and are listed in Figure 3A. The number of
miRNAs that showed downregulation in tumor samples (n=31) as
well as in cancer cell lines (n=23) were higher than the number of
upregulated (n=25 in tumor tissues, n=5 in cell lines) miRNAs.
This is in agreement with previously published miRNA profiling
Table 1. Patient data.
Sample General Classification Age Grade /Stage
Tumor 1 Borderline carcinoma 57 -
Tumor 2 Serous carcinoma low grade 55 Grade 2, stage 3
Tumor 3 Serous carcinoma low grade 73 Grade 2, stage 3
Tumor 4 Clear cell carcinoma 50 -
Tumor 5 Clear cell carcinoma 72 Grade 3
Tumor 6 Serous carcinoma 53 Stage 4
Tumor 7 Serous carcinoma 57 -
Tumor 8 Serous carcinoma - -
Tumor 9 Serous carcinoma 69 -
Tumor 10 Serous carcinoma high grade 76 Grade 3
Tumor 11 Serous carcinoma high grade 74 Grade 3
Tumor 12 Serous carcinoma high grade 64 Grade 3
Tumor 13 Serous carcinoma high grade 66 Grade 3
Tumor 14 Serous carcinoma high grade 69 Grade 3
Tumor 15 Serous carcinoma high grade 48 Grade 3
Tumor 16 Serous carcinoma high grade 46 Grade 3
Tumor 17 Serous carcinoma high grade 86 Grade 3
Tumor 18 Serous carcinoma high grade 52 Grade 3
Tumor 19 Serous carcinoma high grade 64 -
Tumor 20 Serous carcinoma high grade 61 Grade 3, stage 3
Tumor 21 Serous carcinoma high grade 66 Stage 3
Tumor 22 Serous carcinoma high grade 56 Grade 3
Tumor 23 Serous carcinoma high grade 76 Grade 3, stage 3
Tumor 24 Serous carcinoma high grade 64 -
Tumor 25 Serous carcinoma high grade 71 -
Tumor 26 Serous carcinoma high grade 63 Grade 3
Tumor 27 Serous carcinoma high grade 77 -
Tumor 28 Serous carcinoma high grade 68 Stage 3
Tumor 29 Serous carcinoma high grade 80 Grade 3
Tumor 30 Serous carcinoma high grade 64 Grade 3, stage 4
Tumor 31 Serous carcinoma high grade 57 Grade 3, stage 3
Tumor 32 Serous carcinoma high grade 68 -
Tumor 33 Serous carcinoma high grade 64 Grade 4
Tumor 34 Serous carcinoma high grade 51 Grade 4
doi:10.1371/journal.pone.0002436.t001
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be more common than upregulation in cancer [8,13,19,25,26].
miR-221 was the most highly elevated miRNA in both tissues
and cell lines (9-fold and 7-fold respectively), while miR-21 was
significantly decreased in both sample types (3-fold and 9-fold,
respectively) (Table 2). Among the different let-7 family members,
let-7e and let-7f showed more than 2-fold deregulation in at least
60% of the tumor samples. The other let-7 family members (let-7g,
let-7d, let-7c, let-7a-e, let-7i, let-7a, let-7b were not downregulated as
consistently, but each one of them was found decreased 2-fold or
more in at least 20% of the tumors. Overall, 94% of the tumors
had at least one let-7 family member downregulated at least 2-fold.
Cell lines exhibited downregulation of the let-7 family members as
well. let-7f was downregulated more than 4-fold in cell lines, while
let-7d and let-7a-e were also significantly decreased (more than 2.3-
fold and 2-fold, respectively).
We then compared the differentially regulated ovarian miRNAs
identified in this study with those reported in three previous studies
[15–17]. Of a total of 136 miRNAs found deregulated in the
previous studies, 16 were also identified in our study (Figure 3B).
Of these 16 miRNAs, 9 were downregulated (let-7d, miR-106b,
miR-122a, miR-141, miR-183, miR-195, miR-200a, miR-335, mir424)
and 7 were upregulated (miR-100, miR-199a, miR-296, miR-29a,
miR-29c, miR-99a, mir-494). Interestingly, we report 56 miRNAs
that have previously not been found deregulated in ovarian cancer
(Figure 3B).
Predicted gene targets of miRNA genes
miRNAs can regulate a large number of target genes and
several databases based on various algorithms are available for
predicting the targets of selected miRNAs. Target Scan 3.0 and
PicTar were used to predict gene targets of the deregulated
miRNAs identified in this study. Table 2 lists the top 3 predicted
targets according to both Target Scan and PicTar for each
differentially expressed miRNAs. There was little overlap between
the targets identified with the two different databases and only 7
Figure 1. Cluster analysis of miRNA expression. Tree generated by cluster analysis of ovarian cancer tissues and cell lines based on (A) all tested
miRNAs in tissues and cell lines, and (B) differentially regulated miRNAs (Fold change .2.0 or ,0.5 in greater than 60% of the samples) in tissues and
cell lines compared to the normal control HOSE-B cells.
doi:10.1371/journal.pone.0002436.g001
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PLoS ONE | www.plosone.org 3 June 2008 | Volume 3 | Issue 6 | e2436Figure 2. Principal component analysis of ovarian cancer samples (PCA) based on global miRNA expression. Two-dimensional PCA
shows that global miRNA expression patterns are different in ovarian cancer cell lines (indicated in blue), ovarian cancer tissues (indicated in green),
and the non-tumorigenic HOSE-B cells (in red).
doi:10.1371/journal.pone.0002436.g002
Figure 3. Comparisons of miRNA expression in ovarian tissues. (A) The Venn diagram shows the number miRNAs differentially expressed in
ovarian cell lines, in ovarian cancer tissues and in both. For each category, the miRNAs elevated (indicated in red) and downregulated (indicated in
green) are indicated below the diagram. (B) The Venn diagram shows the number of differentially expressed miRNAs identified in the current study
and the number of miRNAs indentified in 3 previous ovarian cancer studies. The miRNAs in common are indicated below the diagram and color-
coded (red: elevated; green: decreased).
doi:10.1371/journal.pone.0002436.g003
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tissues and cell lines.
Gene
Name
Fold
Change Predicted Targets (Target Scan/PicTar)
Tissues: 60% samples, fold .=2.0or,=0.5
mir-221 9.16 TCF12, KIT, CDKN1B, RIMS3, AIP1, NAP1L5
mir-663 4.42 PRRT1, IQSEC2, SCRT1
mir-29a 4.38 PI15, COL3A1, COL4A4, COL1A1, COL4A5 var 2, COL4A5 var 3
mir-142-
3p
4.27 USP6NL, PRLR, FAM44B, FAM44B, AKT1S1, ARNTL
mir-296 3.85 LYPLA2, IQSEC2, RNF44
mir-30a-
5p
3.80 CELSR3, FLJ35954, LYRIC
mir-30e-
5p
3.72 Not available
mir-129 3.60 TNFSF11 variant 2, TNFSF11 variant 1, SOX4
mir-518b 3.43 MCF2L, WDR1, TSN
mir-29c 3.34 PI15, COL3A1, COL4A4, CXXC6, C1QTNF6, COL5A3
mir-605 3.20 VGLL3, PHACTR2, SCAMP1
mir-100 3.16 THAP2, KBTBD8, C4orf16, SMARCA5, BAZ2A, VLDLR
mir-10b 2.94 ARSJ, BDNF, TFAP2C, PRKWNK3 variant 2, PRKWNK3 variant 1,
EPHA8
mir-373* 2.83 KPNA4, ATXN7, SYT4
mir-199a 2.78 ZNF17,DDR1 variant 3, DDR1 variant 1
mir-637 2.71 RBM9, MNT, DAGLA
mir-99a 2.69 THAP2, KBTBD8, C4orf16, SMARCA5, BAZ2A, VLDLR
mir-487b 2.66 NELF, MAP2K4, CDKN2AIP
mir-611 2.66 RIMBP2, GTDC1, NTRK2
mir-594 2.61 Not available
mir-572 2.49 C14orf101, SAP30BP, ADRBK1
mir-525*-
524
2.39 Not available
mir-146b 2.38 Not available
mir-498 2.35 NAP1L3, CXorf1, C9orf5
mir-508 2.26 Not available
mir-524* 0.49 Not available
let-7f 0.49 HMGA2, C14orf28, LIN28B, HMGA2, ARID3B, HIC2
mir-424 0.48 FGF2, KIF1B, TMEM16C
mir-627 0.47 USP9X, KIAA1853, CCDC73
mir-381 0.47 RAB11FIP2, ARID4B, PTCH1, ARID4B, NBEA, IER5
mir-183 0.45 ITGB1, PFN2, SLAIN1, MAL2, PTPN4, CTDSPL
mir-516-
5p
0.44 Not available
mir-361 0.43 Not available
mir-551a 0.43 LPHN1, ERBB4, ZFP36
mir-142-
5p
0.42 ZFPM2, FAM18B, FAM91A1, RPS6KA4, AIP1 ¸ ATP1B1
mir-635 0.41 NARG1, RUNX2, UBE2D3
mir-648 0.41 ONECUT2, BTBD7, FUT9
mir-515-
3p
0.41 CLOCK, FAT2, FMNL3
mir-542-
3p
0.40 YPEL5, SR140, RALGPS1
mir-155 0.40 BACH1, ZNF652, RAB11FIP2, ZNF537, BACH1 variant 2
mir-335 0.39 P18SRP, HLF, CALU, KIAA0256, CALU, N-PAC
mir-206 0.39 TNKS2, UST, GJA1, SERP1, TNKS2, POGK
Gene
Name
Fold
Change Predicted Targets (Target Scan/PicTar)
mir-657 0.39 PRKD3, COPS2, PTPRT
mir-195 0.38 FGF2, KIF1B, TMEM16C, ARL2, LUZP1, FGF2
mir-422a 0.38 LOC389834, HECTD2, PRKAR2A
mir-21 0.37 YOD1, LOC150786, GPR64, PLAG1, RP2, ADNP
mir-622 0.35 INSIG2, NFYA, ATF2
mir-34c 0.35 DLL1, VEZATIN, FLOT2
mir-106b 0.35 EIF5A2, ZNFX1, PKD2, KIAA1404, KIAA1196, ITGB8
mir-346 0.33 BCL6, ACVR2B, NFIB, KIAA0140, BCL6, ROR1
mir-608 0.31 DAGLA, EPHA8, SPRY4
mir-519a 0.31 FLJ31818, TGFBR2, SLAIN1
let-7e 0.31 HMGA2, C14orf28, LIN28B, HMGA2, ARID3B, HIC2
mir-662 0.30 C6orf49, NEGR1, MKX
mir-134 0.27 NIPA1, EML4, PPP1R7, KRAS2 variant b, KRAS2 variant a,
ZFPM2
mir-601 0.26 GOLGA8A, GOLGA8B, GOLGA8E
Cell lines: 60% samples, fold .=2.0or,=0.5
mir-221 7.23 TCF12, KIT, CDKN1B, RIMS3, AIP1, NAP1L5
mir-494 2.83 SOCS6, CNR1, ARHGAP5
mir-190 2.59 OTUD4, NEUROD1, PHF20L1, HSHIN1, STK24, EPC2
mir-508 2.45 Not available
mir-146b 2.4 Not available
mir-424 0.5 FGF2, KIF1B, TMEM16C
mir-98 0.5 HMGA2, C14orf28, LIN28B, HMGA2, ARID3B, HIC2
mir-138 0.5 FOXC1, RMND5A, SLC35F1, LPHN3, FLJ13910, CLK3
mir-380-
5p
0.48 Not available
mir-134 0.48 NIPA1, EML4, PPP1R7, KRAS2 variant b, KRAS2 variant a,
ZFPM2
mir-106b 0.47 EIF5A2, ZNFX1, PKD2, KIAA1404, KIAA1196, ITGB8
mir-200a 0.46 ZEB2, KLF12, ZFR, PPM1E, CUL3, SEC10L1
mir-422a 0.46 LOC389834, HECTD2, PRKAR2A
mir-155 0.46 BACH1, ZNF652, RAB11FIP2, ZNF537, BACH1 variant 2
mir-122a 0.44 GYS1, SLC1A5, 8D6A
let-7d 0.43 HMGA2, C14orf28, LIN28B, HMGA2, HIC2, KIAA1196
mir-141 0.43 ZEB2, KLF12, ZFR, PPM1E, IRS2, KIAA1078
mir-567 0.43 SGMS1, ACLY, GK
mir-634 0.4 PDIK1L, NRXN3, HIPK1
mir-648 0.39 ONECUT2, BTBD7, FUT9
mir-154* 0.38 ZNF281, PRPF3, C10orf86
mir-346 0.37 BCL6, ACVR2B, NFIB, KIAA0140, BCL6, ROR1
mir-493-
3p
0.36 Not available
mir-520g-
520h
0.36 TRIM13, LOC153222, KIAA1826
mir-662 0.3 C6orf49, NEGR1, MKX
mir-519a 0.26 FLJ31818, TGFBR2, SLAIN1
let-7f 0.24 HMGA2, C14orf28, LIN28B, HMGA2, ARID3B, HIC2
mir-21 0.11 YOD1, LOC150786, GPR64, PLAG1, RP2, ADNP
Listed, are mRNAs with fold changes .2.0 or ,0.5 in at elast 60% of the
samples compared to HOSE B cells. HMGA2, BACH1, BCL6, FAM44B, FGF2, CALU,
and TNKS2 were predicted by both Pictar and Target Scan for their respective
miRNAs.
doi:10.1371/journal.pone.0002436.t002
Table 2. Cont.
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TNKS2) for 7 miRNAs (let-7 family, miR-98, miR-155, miR-195,
miR-346, miR-206, miR-335) were shared between these two
databases when the top 3 targets were examined.
Experimental identification of miRNA targets
To further study the potential targets of key ovarian miRNAs,
we overexpressed miR-34c, miR-98, miR-424, and let-7f in 2 ovarian
cancer cell lines (BG-1 and UCI-101). miR-424 and let-7f were
downregulated in both tissues and cell lines (Figure 3A), while miR-
34c and miR-98 were found downregulated in ovarian cancer
tissues and in cell lines, respectively. Figure 4 shows the successful
over-expression of the miRNAs 72 hours following transfection.
We then used Illumina microarrays to investigate mRNA level
changes following the overexpression of these candidates. Tables 3
and 4 list the transcripts that were most significantly altered
following over-expression of the miRNAs in BG-1 and UCI-101
cell lines, respectively. Interestingly, these tables include genes such
as GPX3, MCM7, MSN that have previously been implicated in
ovarian cancer. Among the significantly altered genes (absolute Z-
ratio.1.5), there are 10 known cancer genes (MSN, PIM1, CBL,
COL1A1, COX6C, EVI1, EXT1, HLXB9, PTPN11, TCEA1), 4
tumor suppressor genes (HIF1A, CAV1, GADD45A, PTTG1IP), 26
cell cycle genes (ACAT2, CDK5, FDPS, ID1, LLGL1, MAD2L1,
ANLN, ATAD2, C12orf48, CD9, ECT2, GADD45A, GSTO1, HSPD1,
IPO7, KNTC2, KRT18, MRPS17, NUDT1, PFN1, PRKCA, SFRP1,
SKP2, SNRPA1, VAMP8, WEE1), and 6 genes involved in
chromatin remodeling (ASF1A, GCN5L2, ATAD2, CBX2, CBX4,
NCOA3). Very little overlap was found between the predicted
(Pictar and Target Scan) and experimental targets. Interestingly,
the experimental targets varied according to the cell line used,
suggesting a significant influence of the molecular background on
miRNA target selection. In order to validate the Illumina data,
RT-PCR was performed on 8 genes found to be targets of let-7f
(KIF1A, ASS, FDPS, NTS in UCI-101 cells, and TFF1, EEF1A2,
ESM1, VIM, in BG-1 cells) (Figure 5). We found that, while the
absolute values were different, the trends were the same. KIF1A
and ASS were found elevated in UCI-101, while FDPS and NTS
were downregulated in these cells. TFF1 and EEF1A2 were
confirmed to be elevated in BG-1, while ESM1 and VIM were
downregulated.
Using these experimental targets as a starting point (Table 3 and
Table 4), we used Ingenuity Pathway Analysis (IPA) to reveal
potential diseases, molecular functions, physiological systems, and
canonical pathways associated with expression of these miRNAs in
BG-1 (Table 5) and UCI-101 (Table 6). Not surprisingly, the
analysis identified ‘‘cancer’’ as the main disease associated with
these patterns of expression in both cell lines. GI disease was also
commonly identified. Interestingly, cellular movement, cell cycle,
and cardiovascular functions were systems often found to be
related to these expression patterns. There was little consistency in
the canonical pathways identified through IPA and except for
integrin signaling (found following miR34c or miR98 expression in
BG-1), none of the canonical pathways was found more than once
in Tables 5 and 6. This analysis therefore suggests that while the
general pathways affected by miR-34c, miR-98, miR-424, and let-7f
expression in these two cell lines are related to cancer, the exact
molecular pathways targeted are variable and depend on the cell
line and on the miRNAs. This again points to the high level of
complexity of miRNA target selection and regulation.
Discussion
Previous work has shown that specific miRNA expression
signatures in various human cancers can be associated with
diagnosis, prognosis, and therapy response [27]. Moreover it has
been suggested that specific miRNAs may have crucial roles in the
initiation and/or progression of human cancers through their
effects on various molecular pathways. A better understanding of
miRNA expression in cancer may uncover novel molecular
pathways, or novel mechanisms of activation for known pathways.
Using the Exiqon miRNA array, the most comprehensive miRNA
array available, we have obtained miRNA expression signatures in
ovarian cancer and identified several miRNAs differentially
expressed in ovarian cancer tissues and cell lines, as well as
putative targets for several of these miRNAs.
Figure 4. Forced overexpression of selected miRNAs in ovarian
cancer cell lines. Pre-miR-34c, Pre-miR-98, Pre-miR-424, Pre-let-7f were
overexpressed in BG-1 and UCI-101. The products for each of the
miRNAs is shown in duplicate for the two cell lines used. Significant
overexpression of the miRNAs is confirmed. RT-PCR of 18S RNA is
shown for each condition to demonstrate equal loading.
doi:10.1371/journal.pone.0002436.g004
Figure 5. Validation of illumina arrays data for let-7f. Transcripts
identified by illumina arrays to be altered following let-7f overexpres-
sion are validated by RT-PCR. Fold changes for genes KIF1A, ASS, FDPS,
NTS (in UCI-101 cells), and TFF1, EEF1A2, ESM1, VIM (in BG-1 cells) are
shown and confirm the changes identified by illumina arrays.
doi:10.1371/journal.pone.0002436.g005
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tissues and 14 of these were also aberrantly expressed in ovarian
cancer cell lines (Figure 3A). Overall, there were relatively few
miRNAs found in common between this study and previous
studies (Figure 3B). There are several possible explanations for this
discrepancy. First, the array platform used for the identification of
miRNA is different and may yield different patterns. Second, the
material we utilized as normal control is different than what was
used in previous studies and the choice of normal is known to
influence the outcome of gene profiling analysis [28]. We used
immortalized ovarian surface epithelial cells while two of the other
three miRNA ovarian studies used whole ovaries. We believe that
whole ovarian bulk tissue is not the most appropriate normal
control as the ovary is composed of several cell types and that the
epithelium only represents a small fraction of the ovarian tissue.
The use of an immortalized cell strain also has drawbacks, but we
believe it to be a better approximation of normal ovarian epithelial
tissues than the mixture present in whole ovaries. In any case, the
independent validation of expression patterns is crucial, regardless
of the source of normal tissue or tumors used in the study.
We identify let-7f as highly downregulated in both cell lines and
tumors. Expression of various let-7 miRNAs have been reported to
be down regulated in breast cancers [7], lung cancers [29], thyroid
cancer [11], prostate cancer [13], and ovarian cancer [15–17]. An
association between let-7 downregulation and poor prognosis has
been reported in human lung [29] and breast cancer [7]. The
finding that the let-7 family of miRNAs regulates the expression of
the RAS oncogene family provides a potential molecular basis for
the role of let-7 miRNAs in human cancer [20]. let-7 is therefore
considered to be a tumor suppressor miRNA and, interestingly, let-
7 genes map to loci deleted in multiple types of cancers, including
ovarian cancer [20]. In addition, let-7f has been reported to
promote angiogenesis by targeting anti-angiogenic genes [30]. The
current work as well a previous reports [15–17] showing that
members of the let-7 family are altered in ovarian cancer suggest
that let-7 may represent an important player in this disease. It will
be important to identify let-7 downstream targets relevant to
ovarian tumorigenesis.
The most consistently and highly upregulated miRNA in both
tissues and ovarian cancer cell lines was miR-221 (Table 2). miR-
221 has been shown to be highly upregulated in pancreatic cancers
[12], in glioblastoma [31] and was implicated in thyroid cancer
[32]. miR-221 has been shown to target the oncogene KIT [33] as
well as the tumor suppressor p27kip1 [34].
While miR-21 overexpression has been observed in several
cancers, including glioblastoma [31], breast cancer [7,35], lung
cancer [8], pancreatic cancer [36], human malignant cholangio-
cyte cell lines [37] and colon cancer [38], we found this gene
highly downregulated in our samples. As a matter of fact, miR-21
was the most significant downregulated miRNA in ovarian cancer
when our data was averaged across all samples and cell lines. Our
finding is counter-intuitive since it has been found that miR-21
downregulation was associated with increased apoptosis and
decreased cell proliferation [35]. miR-21 was suggested to function
as an oncogene modulating tumorigenesis through regulation of
genes such as BCL2 [35], PTEN [37] and PDCD4 [39]. We are
currently investigating the possible targets of miR-21 in our cells as
well as the possible reasons behind its downregulation in our
Table 3. Top 10 up-regulated and down regulated genes
after over expression of mir-34c, mir-98, mir-424 and let-7f in
BG-1 cell line.
mir-34c mir-98 mir-424 let-7f
Symbol Z-ratio Symbol Z-ratio Symbol Z-ratio Symbol Z-ratio
GFPT1 3.59 HIST1H4C 6.34 AGRN 4.92 TFF1 8.19
ALOX5AP 3.41 CCDC58 4.44 BAT2 4.34 EEF1A2 7.89
NT5C3 3.36 ABCA1 4.28 GNG12 4.27 S100P 7.61
SUMF2 3.33 RPS7 4.11 C20orf149 4.27 BMP7 6.35
SSR1 3.28 ALOX5AP 4.09 SUMF2 4.27 CRABP2 5.69
RND3 3.25 SLC38A1 4.04 SLC31A1 4.06 C3orf57 5.68
TSNAX 3.03 DBT 3.92 NOMO1 4.03 PRSS8 5.64
C14orf129 2.96 NRIP3 3.88 PABPC3 3.97 KRT19 5.56
ASF1A 2.96 CUEDC1 3.87 ANPEP 3.96 FBP1 5.23
GTF2H3 2.90 C10orf116 3.82 WASF2 3.91 CLDN3 5.21
ECHDC2 -2.57 ZNF259 23.48 GCN5L2 22.95 MSN 25.96
MCM7 22.59 WDR58 23.54 ZNF265 22.96 G0S2 25.99
ARHGAP17 22.71 MLF2 23.59 CCDC14 23.02 GPX1 26.00
PIM1 22.71 FLJ90652 23.60 EIF2B5 23.04 TM4SF1 26.02
C8orf13 22.74 GPSN2 23.81 GPX3 23.09 GSTP1 26.06
FASN 23.03 LLGL1 24.13 SLC37A4 23.30 FSTL1 26.09
LEPREL2 23.43 ACTG1 24.81 C16orf48 23.35 IL1A 26.49
C8orf55 23.46 MRCL3 25.08 NPEPL1 23.40 PRG1 26.67
GPX3 23.53 FKSG30 25.22 MAP4K2 23.42 ESM1 27.51
NNMT 23.54 ACTB 25.91 KLF9 23.49 VIM 27.78
doi:10.1371/journal.pone.0002436.t003
Table 4. Top 10 up-regulated and down regulated genes
after over expression of mir-34c, mir-98, mir-424 and let-7f in
UCI-101 cell line.
mir-34c mir-98 mir-424 let-7f
Symbol Z-ratio Symbol Z-ratio Symbol Z-ratio Symbol Z-ratio
FLNC 5.03 HIST1H4C 5.85 HIST1H4C 5.27 KIF1A 7.89
MT1A 4.17 PSAT1 4.02 ID1 3.65 ASS 7.41
AKNA 4.1 ATP5E 3.93 IRX3 3.52 ASNS 5.47
ID1 3.73 COX7A2 3.61 ID3 3.4 C6orf48 4.77
MT2A 3.52 NDUFA1 3.58 EBPL 3.32 ATF5 4.36
EIF4EBP1 3.44 SARS 3.49 CXXC5 2.88 IGFBP5 4.36
KRT10 3.39 RPS3A 3.47 ATP5E 2.83 SFRS5 4.08
SARS 3.34 RPL14 3.12 ALDH9A1 2.8 PHGDH 3.99
SERPINE1 3.32 ERH 3.03 KRTCAP2 2.73 SOX21 3.88
SOST 3.3 ATP5O 2.98 COX7A2 2.63 IARS 3.73
UBA2 22.56 IPO4 22.5 CMPK 22.7 ACLY 23.56
DDX39 22.62 OAT 22.54 CLASP2 22.8 C8orf52 23.61
E2F3 22.68 GTF3C3 22.66 ITGAV 22.87 HES6 23.97
HIF1A 22.74 SGK 22.74 C13orf23 22.9 C6orf173 24.12
LOC441087 22.74 HES6 22.75 TSNAX 22.96 DHCR7 24.32
EVI5 22.78 XRCC6BP1 22.76 CAND1 23.02 DHCR24 24.61
COPS2 22.78 HMBS 22.78 TMEM119 23.2 FDFT1 24.91
PVRL3 22.83 NUDCD2 22.83 MAD2L1 23.23 ACAT2 25.53
ALPP 22.93 CDK5 23.12 PIGK 23.28 FDPS 25.55
FDFT1 22.96 TGFBR3 23.25 ARHGAP12 23.49 NTS 25.62
doi:10.1371/journal.pone.0002436.t004
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tissue-specific, which would explain differences in the roles of
various miRNA in different tissues.
Other miRNAs found differentially expressed in both tissues
and cell lines are miR-146b, miR-508, miR-106b, miR-134, miR-155,
miR-346, miR-422a, miR-424, miR-519a, miR-648, miR-662.
Several of these miRNAs have been implicated in the other
malignancies or in the control of growth and apoptosis. For
example, miR-134 downregulated cell growth, and miR-155
increased cell growth in lung carcinoma cells, A549 [40]. The
contribution of each of these players to ovarian tumorigenesis
remains to be determined.
miR-34c has recently been shown to be a transcriptional target of
p53 [41,42] and can suppress proliferation and colony formation
in soft agar in neoplastic epithelial ovarian cells [42]. Interestingly,
we found miR-34c deregulated in ovarian cancer tissues and this
finding suggests that miR-34c may play a role in ovarian
tumorigenesis through its role in the p53 pathway.
Because of the tissue specificity of the miRNAs, different sets of
miRNAs are likely to be upregulated or downregulated in cancers
of different cellular origins, although it has been reported that
miRNA signatures of different cancer types especially epithelial
would share some individual miRNAs [38]. Of the miRNAs that
were reported here to be differentially expressed in ovarian cancer,
several have been similarly deregulated in other cancers. Overall,
31 miRNAs identified in the current study have also been reported
de-regulated in other cancer (data not shown). Moreover, 16
miRNAs identified here have previously been reported to be
altered in ovarian cancer (Figure 3b). More interestingly, we
identify 56 miRNAs that have not previously been found
differentially expressed in ovarian cancer. These miRNA may
play a role in ovarian tumorigenesis and are currently being
investigated.
In order to identify potential targets of the differentially
expressed miRNAs in ovarian cancer we searched two major
databases, PicTar and Target Scan. We found that there was very
little overlap between the predicted targets of each algorithm.
Indeed, only 7 (FAM44B, BACH1, BCL6, HMGA2, CALU,
FGF2, and TNKS2) predicted targets were shared between these
two databases. This result illustrates the well-documented
difficulties of predicting targets for miRNA [43]. Moreover, it is
possible that targets may depend on the cellular environment,
(relative ratios of different potential targets may affect the ones
most likely to be downregulated) adding another layer of
complexity in miRNA target selection. In order to experimentally
investigate the changes in mRNA levels, we over-expressed 4
different miRNA candidates (miR-98, miR-424, miR-34c and let-7f)
in 2 cell lines and assessed transcript levels using an Illumina
oligonucleotide array. Clearly, this approach can only identify
miRNA targets that have altered mRNA levels (as opposed to
translation inhibition targets), but it has previously been shown
that miRNAs can downregulate the levels of a large number of
transcripts [44]. While some of the transcripts altered may not
represent direct targets of the corresponding miRNA, further
analysis of individual candidate mRNAs can provide evidence as
to whether they represent direct or secondary targets. Ingenuity
Pathway Analysis of the targets revealed a number of pathways
and system potentially regulated by the overexpressed miRNAs
(Table 5 and Table 6). Interestingly, the predicted pathways were
not consistent between the 2 cell lines and again suggested that
miRNA target selection and therefore, miRNA function is highly
tissue dependent.
When the predicted targets (obtained with PicTar and Target
Scan) were compared with the experimental targets obtained by
Illumina microarray, we observed no overlap. This could be due to
a number of reasons. First, the algorithms for the identification of
miRNA targets may preferentially identify targets that result in
translational repression, which obviously would not be identified
by our microarray experiment. Moreover, as discussed previously,
it is likely that the miRNA targets are tissue-specific. In agreement
with this possibility is the fact that the targets we identified
experimentally were completely different in the two cell lines we
used. Interestingly, most of the highly up regulated and down
regulated (top 10) genes have already been reported to have roles
in cancer or other cellular activities related to cancer (Table 3 and
4), such as GSTP1 [45,46], HIF-1 [47,48], and SGK [49].
In this study we have identified miRNAs differentially expressed
in ovarian cancer. As a first step in determining their roles in
ovarian tumorigenesis, we have started to identify targets of these
miRNAs. We show that the predicted targets are different from the
experimental and that experimental targets vary according to the
cellular background in which miRNAs are expressed. It will
therefore be important to methodically study each miRNAs in
several models in order to clarify their roles in ovarian cancer. In
addition, a combination of overexpression/targeting events by
miRNA along with protein array technology will be crucial in
identifying the miRNA:mRNA players of ovarian cancer. The
picture that is likely to emerge is a highly complex set of
interactions between miRNAs and target mRNAs. A better
understanding of these pathways will bring us yet closer to an
understanding of the molecular mechanism underlying this disease
and hopefully to novel approaches for detection and therapy.
Materials and Methods
Cell Lines and Tissue Samples
Ovarian cancer lines BG-1, UCI-101, HEY, OVCA420,
OVCA432, OVCA433, OVCAR2, OVCAR3 and OVCAR5
cells were cultured in McCoy’s 5A growth medium (Invitrogen)
supplemented with 10% fetal bovine serum (FBS) and antibiotics
(100 units/ml penicillin and 100 mg/ml streptomycin). Ovarian
cancer cell line OV90 was cultivated in MCBD 105 medium
(Sigma)+Medium 199 (Invitrogen) supplemented with 15% FBS
and antibiotics. HOSE-B, an ovarian surface epithelial cell line
immortalized with E6 and E7 [50], was cultivated in RPMI1640
supplemented with 10% FBS, antibiotics and 5 ng/ml EGF.
Eighteen frozen primary ovarian cancers were obtained through
the Collaborative Human Tissue Network Gynecologic Oncology
Group (Children’s Hospital, Columbus, OH). In addition, nine
frozen primary ovarian cancer samples and seven RNA samples
(from primary ovarian cancer tissues) were obtained from the
Department of Pathology of The Johns Hopkins Medical
Institutions (Baltimore, MD). Histological classification of all the
tissues is presented in Table 1 and all samples were found to
contain greater that 80% cancer cells.
RNA extraction & quantification
Total RNA was obtained using Trizol (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. RNA was
quantified and assessed using the RNA 6000 Nano Kit and 2100
Bioanalyzer (Agilent Technologies UK Ltd, West Lothian, UK).
miRNA microarray hybridization
miRCURY
TM LNA miRNA Arrays (Exiqon), consisting of
control probes, mismatch probes and 1458 capture probes,
perfectly matched probes for all miRNA in all organisms as
annotated in miRBase Release 8.1, July 2006 (human miRBase
8.2 is also covered) were used in this study. The capture probes
miRNAs in Ovarian Cancer
PLoS ONE | www.plosone.org 9 June 2008 | Volume 3 | Issue 6 | e2436cover 92.3% of miRNAs annotated in miRBAse 9.0. The control
probes includes 10 spike-in control probes to assure optimal
labeling and hybridization, eight negative capture probes and
twelve capture probes that hybridize to small nuclear RNAs. RNA
labeling and hybridization was completed according to the
manufacturer’s instructions. Briefly, RNA from each sample was
labeled with Cy3 using miRCURY
TM LNA miRNA Array
labeling kit. After labeling, the samples were loaded onto the
microarray slide and incubated 16–18 hrs at 60uC. After
hybridization the slides were washed, dried by centrifugation,
and scanned using the Agilent Microarray Scanner (model
G2565B).
miRNA microarray analysis
Average values of the replicate spots of each miRNA on the
microarray were normalized using global normalization. The
correction factor was calculated by dividing the sum of intensities
of each sample by the average of all the samples. The normalized
values were calculated by multiplying average intensities of each
miRNA with the correction factor. The expression levels for each
tumor sample were then computed relative to the expression
observed in the non-tumorigenic HOSE-B cells. The JMP 6.0.0
software (SAS Institute Inc, Cary, NC) was used for hierarchical
clustering, generation of heat maps, and principal component
analysis (PCA). Agglomerative hierarchical clustering was applied
using the complete linkage method to investigate whether there
was evidence for natural groupings of tumor samples based on
correlations between gene-expression profiles. The miRNA array
data is MIAME compliant has been submitted to the NCBI Gene
Expression Omnibus (GEO) database (Accession: GSE10150).
miRNA over-expression in cancer cell lines
Cell lines were tranfected with Pre-miR
TM miRNA precursor
(Ambion) and control siRNA (Dharmacon) in 24 well plates using
siPORT Neo-FX
TM (Ambion) according to the manufacturer’s
protocol. Three days post-transfection, RNA was prepared using
RNeasy kit (Qiagen) and changes in RNA levels analyzed using
illumina microarrays (below). The changes in miRNA levels were
monitored using N-code cDNA synthesis and qPCR.
Illumina Microarray analysis and validation
Biotinylated cRNA was prepared using the Illumina RNA
Amplification Kit (Ambion, Inc., Austin, TX) according to the
manufacturer’s directions starting with approximately 500 ng total
RNA. Samples were purified using the RNeasy kit (Qiagen,
Valencia, CA). Hybridization to the Sentrix HumanRef-8
Expression BeadChip (Illumina, Inc., San Diego, CA), washing
and scanning were performed according to the Illumina BeadSta-
tion 5006manual (revision C). Array data processing and analysis
was performed using Illumina Bead Studio software. The illumina
microarray data is MIAME compliant has been submitted to the
NCBI Gene Expression Omnibus (GEO) database.
Validation of the expression patterns of the following genes
KIF1A, ASS, FDPS, NTS (in UCI-101), and TFF1, EEF1A2,
ESM1 VIM (in BG-1) was performed using RT-PCR as previously
described [51]. Primer sequences are available from the authors.
Gnes diffentially expressed following miRNA expression were
analyzed using Ingenuity Pathway Analysis (Redwood City,
California).
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